



Shaping Tomorrow's Nephrology: **Insight-Driven Kidney Care**


**KSN** SEOUL, KOREA  
**2026**

The 46th Annual Meeting of the Korean Society of Nephrology



Jun 11 (Thu) – 14 (Sun), 2026  
COEX, Seoul, Korea

## Curriculum Vitae

<b>Name</b>	Nicholas Webb	
<b>Country</b>	UK	
<b>Affiliation</b>	Head of Nephrology Clinical Strategy Sobi Honorary Professor of Paediatric Nephrology, University of Manchester UK	
<b>Department</b>	Pediatrics-Nephrology	

### Bio

Nick graduated in Medicine from the University of Nottingham in 1986. Following training positions in the UK, Australia and Canada he was appointed Consultant Paediatric Nephrologist at the Royal Manchester Children's Hospital in 1994. In 2013 he was awarded an Honorary Chair in Paediatric Nephrology at the University of Manchester.

His research has focused on the development of new therapies and therapeutic regimens for the treatment of childhood kidney disease. He designed and led PREDNOS and PREDNOS 2, two large multicentre studies investigating the optimal use of corticosteroid therapy for the treatment of childhood idiopathic nephrotic syndrome. He has over 160 peer reviewed publications with a h-index of 51 and has been awarded over £6m for his personal research. He co-authored Clinical Paediatric Nephrology and the Oxford Handbook of Paediatric Nephrology, two major textbooks with substantial worldwide readership.

Nick transitioned to the pharmaceutical industry in 2018. At Novartis he led the Phase 2 and 3 development of iptacopan for the treatment of C3G, IgAN and other rare glomerular diseases. In 2024 he was appointed Vice President and Head of Clinical Strategy: Nephrology at Sobi, where he works across multiple teams focusing on the licensing and further development of pegcetacoplan for the treatment of C3G and primary IC-MPGN in adults and children.